Richard McFetridge

797 citations

19 papers · 601 indexed · h-index 12

Co-authors: Rocio D. Marchese Luwy Musey Daniel M. Musher Susan B. Manoff Jon E. Stek Jonathan Hartzel Michael J. Dallas Jeffrey L. Silber
Topics: Pneumonia and Respiratory Infections (18 papers)Respiratory viral infections research (11 papers)Pneumocystis jirovecii pneumonia detection and treatment (9 papers)
Cited by: Microbiology Epidemiology Immunology
Journals: The Journal of Infectious Diseases Vaccine The Pediatric Infectious Disease Journal
Partner nations: United States Israel Australia

In The Last Decade

Richard McFetridge

19 papers receiving 588 citations

Peers

Countries citing papers authored by Richard McFetridge

Since Specialization

Citations

This map shows the geographic impact of Richard McFetridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard McFetridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard McFetridge more than expected).

Fields of papers citing papers by Richard McFetridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard McFetridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard McFetridge. The network helps show where Richard McFetridge may publish in the future.

Co-authorship network of co-authors of Richard McFetridge

This figure shows the co-authorship network connecting the top 25 collaborators of Richard McFetridge. A scholar is included among the top collaborators of Richard McFetridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard McFetridge. Richard McFetridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1) 2023 ·Vaccine ·Federico Martinón‐Torres,Jacek Wysocki,Leszek Szenborn,(unknown),Airi Põder,Ron Dagan,Peter Richmond,Christopher L. Gilbert,(unknown),(unknown),Robert Lupinacci,Richard McFetridge,Richard T. Wiedmann,(unknown),(unknown),Natalie Banniettis,Luwy Musey,Kara Bickham,(unknown)	15
2	Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2) 2023 ·Vaccine ·Thomas Benfield,(unknown),Piero Valentini,(unknown),Ron Dagan,Peter Richmond,(unknown),(unknown),Robert Lupinacci,Richard McFetridge,(unknown),Frederick Wittke,Natalie Banniettis,Luwy Musey,Kara Bickham,(unknown)	15
3	A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED) 2023 ·Vaccine ·Robert Lupinacci,Richard Rupp,Orasri Wittawatmongkol,Jake D. Jones,(unknown),Betül Ulukol,Ron Dagan,Peter Richmond,Jon E. Stek,(unknown),Sandra Koseoglu,Gretchen Tamms,Richard McFetridge,Jianing Li,(unknown),Luwy Musey,Natalie Banniettis,Kara Bickham	26
4	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study 2022 ·Blood Advances ·Charles T. Quinn,Richard T. Wiedmann,Daniel Jarovsky,Eduardo López‐Medina,(unknown),(unknown),(unknown),Qiong Shou,Ron Dagan,Peter Richmond,Kristen A. Feemster,Richard McFetridge,Gretchen Tamms,Robert Lupinacci,Luwy Musey,Kara Bickham	6
5	A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION) 2022 ·Vaccine ·Androniki Bili,Scott Dobson,(unknown),Wanatpreeya Phongsamart,Peninnah Oberdorfer,Pope Kosalaraksa,Ron Dagan,Peter Richmond,Marissa B. Wilck,(unknown),(unknown),Richard McFetridge,Gretchen Tamms,Rong Fu,Robert Lupinacci,Luwy Musey,Natalie Banniettis,Kara Bickham	10
6	A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN) 2022 ·Vaccine ·Natalie Banniettis,Jacek Wysocki,Leszek Szenborn,Wanatpreeya Phongsamart,Punnee Pitisuttithum,(unknown),Peter Richmond,(unknown),Ron Dagan,(unknown),(unknown),Robert Lupinacci,Richard McFetridge,Gretchen Tamms,(unknown),Luwy Musey,Kara Bickham	11
7	336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED) 2022 ·Robert Lupinacci,Richard Rupp,Orasri Wittawatmongkol,Jake D. Jones,(unknown),Betül Ulukol,Ron Dagan,Peter Richmond,Jon E. Stek,(unknown),Sandra Koseoglu,Gretchen Tamms,Richard McFetridge,Jianing Li,(unknown),Luwy Musey,Natalie Banniettis,Kara Bickham,Andrew Tran,(unknown)	2
8	1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION) 2021 ·Open Forum Infectious Diseases ·(unknown),Scott Dobson,(unknown),Wanatpreeya Phongsamart,Peninnah Oberdorfer,Pope Kosalaraksa,Ron Dagan,Marissa B. Wilck,(unknown),(unknown),Richard McFetridge,Rong Fu,Robert Lupinacci,Luwy Musey,Kara Bickham	5
9	1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN) 2021 ·Open Forum Infectious Diseases ·Natalie Banniettis,Jacek Wysocki,Leszek Szenborn,Wanatpreeya Phongsamart,Punnee Pitisuttithum,(unknown),Ron Dagan,(unknown),(unknown),(unknown),Luwy Musey,Kara Bickham,Gretchen Tamms,Richard McFetridge,Robert Lupinacci	3
10	A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants 2020 ·The Pediatric Infectious Disease Journal ·Heather Platt,David Greenberg,Bruce Tapiéro,(unknown),Nicola P. Klein,David Hurley,Tulin Shekar,Jianing Li,(unknown),Shu‐Chih Su,Katrina M. Nolan,Camilo J. Acosta,Richard McFetridge,Kara Bickham,Luwy Musey,(unknown)	43
11	A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants 2019 ·Human Vaccines & Immunotherapeutics ·Randall G. Rupp,David Hurley,(unknown),(unknown),Katrina M. Nolan,Richard McFetridge,(unknown),Chitrananda Abeygunawardana,Michael A. Winters,Hari Pujar,(unknown),Luwy Musey	53
12	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age 2018 ·Vaccine ·(unknown),Charles P. Andrews,Steven Folkerth,Richard Rupp,David Greenberg,Richard McFetridge,Jonathan Hartzel,Rocio D. Marchese,Jon E. Stek,Chitrananda Abeygunawardana,Luwy Musey	33
13	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants 2018 ·Vaccine ·David Greenberg,(unknown),Timo Vesikari,(unknown),David Hurley,Richard McFetridge,Michael J. Dallas,Jonathan Hartzel,Rocio D. Marchese,Beth-Ann Coller,Jon E. Stek,Chitrananda Abeygunawardana,Michael A. Winters,John E. MacNair,Narahari S. Pujar,Luwy Musey	78
14	Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults 2015 ·Vaccine ·Richard McFetridge,Ajoke Sobanjo-ter Meulen,Steven Folkerth,J. Hoekstra,Michael J. Dallas,(unknown),Rocio D. Marchese,(unknown),Wendy J. Watson,Jon E. Stek,Jonathan Hartzel,Luwy Musey	49
15	Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine 2014 ·The Pediatric Infectious Disease Journal ·Ajoke Sobanjo-ter Meulen,Timo Vesikari,(unknown),(unknown),Michael J. Dallas,(unknown),Richard McFetridge,Jon E. Stek,Rocio D. Marchese,Jonathan Hartzel,Wendy J. Watson,Luwy Musey	47
16	Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults 2011 ·Human Vaccines ·Daniel M. Musher,Susan B. Manoff,Richard McFetridge,Charles Liss,Rocio D. Marchese,Jennifer Raab,Adriana M. Rueda,(unknown),(unknown)	65
17	Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle‐Aged and Older Adults 2010 ·The Journal of Infectious Diseases ·Daniel M. Musher,Susan B. Manoff,(unknown),Richard McFetridge,Rocio D. Marchese,(unknown),Frances B. Alvarez,(unknown),Michael D. Blum,Jeffrey L. Silber	126
18	Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine (PN23), and immunogenicity and safety of 2nd and 3rd doses in older adults 2010 ·International Journal of Infectious Diseases ·Susan B. Manoff,Richard McFetridge,(unknown),Rocio D. Marchese,(unknown),Adriana M. Rueda,Daniel M. Musher	3
19	EFFICACY AND SAFETY OF PENTAVALENT HUMAN-BOVINE REASSORTANT ROTAVIRUS VACCINE WHEN ADMINISTERED WITH GREATER THAN 10 WEEKS BETWEEN DOSES 2010 ·The Pediatric Infectious Disease Journal ·Michelle G. Goveia,(unknown),Robbin Itzler,Richard McFetridge,Michael J. Dallas,Barbara J. Kuter	11

About Richard McFetridge

Richard McFetridge is a scholar working on Epidemiology, Microbiology and Immunology, having authored 19 papers that have together received 601 indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (18 papers), Respiratory viral infections research (11 papers) and Pneumocystis jirovecii pneumonia detection and treatment (9 papers). The work is most often cited by research in Microbiology (175 citations), Epidemiology (545 citations) and Immunology (52 citations). Richard McFetridge has collaborated with scholars based in United States, Israel and Australia. Frequent co-authors include Rocio D. Marchese, Luwy Musey, Daniel M. Musher, Susan B. Manoff, Jon E. Stek, Jonathan Hartzel, Michael J. Dallas, Jeffrey L. Silber, Michael D. Blum and Frances B. Alvarez. Their work appears in journals such as The Journal of Infectious Diseases, Vaccine and The Pediatric Infectious Disease Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact